Weight gain associated with atypical antipsychotic drugs: mechanisms and management

References

• Regal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int. J. Obes. Relat. Metab. Disord. 22(1), 39–47 (1998).
   Google Scholar
• National Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obesity Res. 6\(Suppl. 2) 50s-63s (1998).
   Google Scholar
• Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemic of obesity and diabetes in the United States. JAIVIA 286, 1195–1200 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon HL, Law A, Hohman KE. The problem of overweight in hospitalized psychotic patients. Psychiatry Q.34, 69–82 (1960).
   PubMedGoogle Scholar
• Allison DB, Fontaine KR, Moonseong H. The distribution of body mass index among individuals with and without schizophrenia.j Clin Psych. 60,215–220 (1999).
   Google Scholar
• Mukherjee S, Decina P, Bocola V Diabetes mellitus in schizophrenic patients. Compr. By& 37,68–73 (1996).
   PubMed Web of Science ®Google Scholar
• Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. j Clim Psych. 44(2), 42–46 (1983).
   PubMedGoogle Scholar
• Bernstein JG. Induction of obesity by psychotropic drugs. Ann. NY Acad. Sci. 499,203–215 (1987).
   PubMedGoogle Scholar
• Baptista T Bodyweight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psych. Land. 100,3–16 (1999).
   PubMedGoogle Scholar
• Ananth J, Venkatesh, R, Burgoyne K, Gunatilake S. Atypical antipsychotic drug use and diabetes. Submitted to fiychosomatics Ptychotherapy (2001).
   Google Scholar
• Klett CJ, Caffey EM Jr. Weight changes during treatment with phenothiazine derivatives. Neuropsych. 2, 102–108 (1960).
   Google Scholar
• Holden JM, Holden UR Weight changes with schizophrenic psychosis and psychotropic drug therapy. P.Tchosomatics 11(6), 551–561 (1970).
   PubMedGoogle Scholar
• Branchey MET, Lee JH, Amin R, Simpson GM. High- and low-potency neuroleptics in elderly psychiatric patients. JAIVIA 239(18), 1860–1862 (1978).
   PubMedGoogle Scholar
• Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. BE j Psych. 153, 214–217 (1988).
   Google Scholar
• Dufresne RL, Valentino D, Kass DJ. Thioridazine improves affective symptoms in schizophrenic patients. Ptychophatm. Bull. 29(2), 249–255 (1993).
   Google Scholar
• Doss FVV. The effect of antipsychotic drugs on body weight: A retrospective review. J. Clim Psych. 40,528–530 (1979).
   PubMed Web of Science ®Google Scholar
• Bernstein JG. Psychotropic drug induced weight gain: mechanisms and management. Cita. Neurophatm.11 (Suppl. 1),s194-s206 (1988).
   Google Scholar
• Rockwell WJ, Ellinwood EH Jr, Trader DW Psychotropic drugs promoting weight gain: health risks and treatment implications. S. Med Jour 76(11), 1407–1412 (1983).
   PubMedGoogle Scholar
• Brady KT Weight gain associated with psychotropic drugs. S Med JOLIE 82,611–617 (1989).
   Google Scholar
• Bhavnani SM, Levin GM. Antipsychotic agents: A survey of the prevalence, severity and burden of side effects. Int. Clin. Psychopharm. 11 (1), 1–12 (1996).
   Google Scholar
• Allison DB, Casey DE. Antipsychotic- induced weight gain: A review of the literature. j Clin. Psych. 62\(Suppl. 7), 22-31(2001).
   Google Scholar
• Casey DE. The relationship of pharmacology to side effects. j Clin. Psych. 58\(Suppl. 10), 55–62 (1997).
   Google Scholar
• Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. j Clin. Psych. 50,329-338 (1989).
   Google Scholar
• Naber D, Hippius H. The European experience with clozapine. Hasp. Comm. Psych. 41,886–890 (1990).
   PubMedGoogle Scholar
• Povlsen UJ, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psych. Land 71,176–185 (1985).
   Google Scholar
• Hummer M, Kemmler WC, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW Weight gain induced by clozapine. Eur Neuropsychopharm. 5(4), 437–440 (1995).
   Google Scholar
• Wirshing DA, Wirshing WC, Kysar L eta] Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psych. 60(6), 358–363 (1999).
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ. Double- blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. PTchopharm. 17,407–418 (1997).
   Google Scholar
• Tohen M, Zarate CA. Antipsychotic agents and bipolar disorder. J. Clin. Psych. 59\(Suppl. 1), 38–48 (1998).
   Google Scholar
• Guile C, Sachs GS, Ghaemi SN. A naturalistic comparison of clozapine, risperidone and olanzapine in the treatment of bipolar disorder. J. Clin. Psych. 61(9), 638–642 (2000).
   Google Scholar
• Frankenburg FR, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change. Biol. Psych. 43,520–524 (1998).
   PubMedGoogle Scholar
• George TP, Sernyak MJ, Ziedonis DM, Woods SW Effects of clozapine on smoking in chronic schizophrenic out-patients. J. Clin. Psych. 156,344–346 (1995).
   Google Scholar
• Grunberg NE. Smoking cessation and weight gain. N Engl. I Med. 324,768–769 (1991).
   PubMedGoogle Scholar
• Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine induced weight gain: prevalence and clinical relevance. Am. J. Psych. 149,68–72 (1992).
   PubMed Web of Science ®Google Scholar
• Bai YM, Lin CC, Chen JY, Lin CY. Weight gain among patients on clozapine. Psych. Ser. 50(5), 704–705 (1999).
   Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am. J. Psych. 151(6), 825–835 (1994).
   Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl. I Med. 348, 16–22 (2002).
   Google Scholar
• Conley RR, Mahmoud R and Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Presented at the annual meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico, Dec 12–16 (1999).
   Google Scholar
• Peuskens JA on behalf of Risperdione Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multinational multicenter double-blind parallel group study versus haloperidol. BE Psych. 166,712–726 (1995).
   PubMedGoogle Scholar
• Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Slavesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations Acta Psychiatr Land. 88,395–402 (1993).
   Google Scholar
• Csernansky J, Okamoto A. Risperidone versus haloperidol in the prevention of relapse in chronic schizophrenia and schizoaffective disorders: a long-term double-blind comparison. Eur. Neuropsychopharm. 9\(Suppl. 5), s268 (1999).
   Google Scholar
• Cohen S, Glazewski R, Khan S, Khan A. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J. Clin. Psych. 62,114–116 (2001).
   Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of `seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Rio. Psych. 42(4), 233–246 (1997).
   Google Scholar
• Peuskens JA. Comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psych. Land. 96,265–273 (1997).
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA. Quetiapine in patients with schizophrenia. Arch. Gen. Psych. 54,549–557 (1997).
   PubMed Web of Science ®Google Scholar
• Tandon R, Harrigan E, Zorn S. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential. I Serotonin Res. 4,159–177 (1997).
   Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/ day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a six week placebo-controlled trial. Neuropsychophatmacology 20(5), 491–505 (1999).
   Google Scholar
• Keck P Jr, Buffenstein A, Ferguson J etal. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4 week placebo-controlled trial. PTchopharmacology140(2), 173–184 (1998).
   Google Scholar
• Weiden P, Simpson G, Kramer T Switching from olanzapine to ziprasidone: clinical effects. Eur. Neuropsychopharm. 9\(Suppl. 5), s264 (1999).
   Google Scholar
• Simpson G, Potkin S, Switch Study Group. Switching from risperidone to ziprasidone. Eur. Neumpsychopharm. 9\(Suppl. 5), s265 (1999).
   Google Scholar
• Arato MO, O'Connor R, Meltzer H. Ziprasidone investigators Study Group. Ziprasidone: efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia. Eur Neuropsychopharm. 7\(Suppl. 2), S214 (1997).
   Google Scholar
• Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. j Clin. Psych. 58\(Suppl. 10), 13–17 (1997).
   Google Scholar
• Zyprexa PDR. Physician Desk Reference. Montvale, NJ, USA, 1641–1645 (1999).
   Google Scholar
• Martinez JM, Russell JM, Mackell JA. Average dose and weight gain: olanzapine versus risperidone. In: New research program and abstracts of the 152nd annual meeting of the American Psychiatric Association, Abstract NR136, Washington DC, USA, May 15–20, (1999).
   Google Scholar
• Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. J. Clin. Psych. 60\(Suppl. 21), 16–19 (1999).
   Google Scholar
• Conley RR, Meltzer HY. Adverse events related to olanzapine. j Clin. Psych. 61 (Suppl. 8), 26–29, discussion 30 (2000).
   Google Scholar
• Gupta, S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine induced weight gain. Ann. Clin. Psych. 10,39 (1999).
   Google Scholar
• Wildocher D, Allilaire JF, Guerard des Lauriers A, Lacubrier V. Amisulpiride neuroleptic and antinegative action. Encephale 16,159–163 (1990).
   Google Scholar
• Leucht S, Pitschel-Walz G, Engel RR, Kissling W Amisulpiride, an unusual 'atypical' antipsychotic: a metaanalysis of randomized controlled trials. Am. PTchiatry 159,177–179 (2002).
   PubMedGoogle Scholar
• Baptista T, Alastre T, Contreras Q et al. Effects of the antipsychotic drug, amisulpiride, on reproductive system hormones in healthy men: Relationship with body weight regulation. Phatmacopsychiatry30, 256–262 (1997).
   PubMedGoogle Scholar
• Peuskens J, Bech P, Moller HJ, Bale R Fleuret G, Rein W Amisulpiride vs. Risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpiride Study group. Psychiatry Res. 88,107–117 (1999).
   Google Scholar
• Rein W, Tuijanski S, Favennec-Meidinger C. Amisulpiride, an atypical antipsychotic — safety profile. Poster presented at Xth WPA Congress, Madrid, Spain, August 23–28, (1996).
   Google Scholar
• Robinson RG, McHugh PR, Folstein ME Measurement of appetite disturbances in psychiatric disorders. J. Psych. Res. 12,59–68 (1975).
   Google Scholar
• Amdisen A. Drug produced obesity. Experiences with chlorpromazine, perphenazine and clopenthixol. Dan. Med. Bull. 11,182–189 (1964).
   PubMedGoogle Scholar
• Johnson DAW, Breen M. Weight changes with depot neuroleptic maintenance therapy. Acta Psych. Land. 59,525–528 (1979).
   PubMedGoogle Scholar
• Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J. Clin. Psych. 55(Suppl. B),157–160 (1994).
   Google Scholar
• Stanton JM. Weight gain associated with neuroleptic medication: a review. Schiz. Bull 21,463–472 (1995).
   PubMedGoogle Scholar
• Kinon B, Basson B, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight related health factors in schizophrenia. j Clin. Psych. 62, 92–100 (2001).
   Google Scholar
• Henderson D, Cagliero E, Gray C eta]. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five year naturalistic study. Am. j Psych. 57(6), 975–981 (2000).
   Google Scholar
• Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int. J. Neuropsychopharmacol 3(4), 339–349 (2000).
   Google Scholar
• Tecott LH, Sun LM, Akana SF eta]. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374(6522), 542–546 (1995).
   Google Scholar
• Casey DE, Zom SH. The pharmacology of weight gain with antipsychotics. j Clin. Psych. 62 (Suppl. 7), 4–10 (2001).
   Google Scholar
• Campfield LA, Smith FJ, Guisez Y, Devos R, Bum P Recombinant mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science 269(5223), 546–549 (1995).
   PubMed Web of Science ®Google Scholar
• Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 22,763–770 (1998).
   Web of Science ®Google Scholar
• Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, lepin and blood lipids in olanzapine treated patients with schizophrenia or related pychoses. j Clin. Psych. 61(10), 742–749 (2000).
   Google Scholar
• Kraus T, Haack M, Schuld A etal. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. j Psych. 156(2), 312–314 (1999).
   Google Scholar
• Ahren B, Larsson H, Wilhelmsson C, Nasman B, Olsson T Regulation of circulating leptin in humans. Endocrine 7(1), 1–8 (1997).
   PubMedGoogle Scholar
• Yamaguchi T, Kamon J, Wald H etal. The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7,941–946 (2001).
   Google Scholar
• Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. j Clin. Bychopharm. 16(5), 403–409 (1996).
   PubMed Web of Science ®Google Scholar
• Hinze-Sekh D, Deuschle M, Weber B, Heuser I, Pollmacher T Effect of co-administration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts plasma levels of cytokines and bodyweight. Bychopharmacology149,163–169 (2000).
   PubMedGoogle Scholar
• Argiles JM, Lopez-Soriano J, Busquets S, Lopez-Soriano FJ. Journey from Cachexia to obesity by TNF. FASEBJ 11,743–751 (1997).
   PubMed Web of Science ®Google Scholar
• Auwerx J, Staels B. Leptin. Lancet 351, 737–742 (1998).
   PubMed Web of Science ®Google Scholar
• Fontaine KR, Heo M, Harrigan EP et al. Estimating the consequences of antipsychotic induced weight gain on health and mortality rate. Psych. Res. 101(3), 277–288 (2001).
   PubMedGoogle Scholar
• Hauner H. The impact of pharmacotherapy on weight management in Type 2 diabetes. Int. J. Obes. 23\(Suppl. 7), S12—S17 (1999).
   Google Scholar
• Winkelman JW. Schizophrenia obesity and obstructive sleep apnea. j Clin. Psych. 62, 8–11 (2001).
   Google Scholar
• Rankinen T, Perusse L, Weisnagel SJ, Snyder EE, Chagon YC, Bouchard C. The human obesity gene map: the 2001 update. Obes. Res. 10(3), 196–243 (2002).
   Google Scholar
• Froguel P, Boutin P Genetics of pathways regulating body weight in the development of obesity in humans. Exp. Biol. Med. (Maywood) 226(11), 991–996 (2001).
   Google Scholar
• Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 13(1), 18–23 (2002).
   Google Scholar
• Boelsterli UA, Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPAR gamma) expression in the liver: insights from models of obesity and Type 2 diabetes. Biochem. Pharmacol 63(1), 1–10 (2002).
   Google Scholar
• Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov M. Effect of clozapine—quetiapine combination therapy on weight and glycaemic control: Preliminary findings. Clin. Drug- Inves. 18, 99–104 (1999).
   Google Scholar
• Jimerson DC, Lesem MD, Kaye WH, Hegg AP, Brewerton TD. Eating disorders and depression: is there a serotonin connection? Bid Psych. 28(5), 443–454 (1991).
   Google Scholar
• Grinspoon S, Gulick T, Askari H etal Serum leptin levels in women with anorexia nervosa. J. Clin. Endocrin. Metabol 81, 3861–3863 (1996).
   PubMed Web of Science ®Google Scholar
• Kaye WH, Gwirtsman HE, George DT, Ebert MET. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch. Gen. Psych. 48(6), 556–562 (1991).
   Google Scholar
• Sullivan PE Mortality in anorexia nervosa. Am. fiych. 152,1073–1074 (1995).
   PubMedGoogle Scholar
• Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR. The clinical course of osteoporosis in anorexia nervosa. JAIVIA 265(9), 1133–1138 (1990).
   Google Scholar
• Klibanski A, Biller BMK, Schoenfeld D, Herzog DB, Saxe V. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J. Clin. Endocrin. Met. 80(3), 898–904 (1995).
   Google Scholar
• Garattini S, Mennini T, Samain R. Reduction of food intake by manipulation of central nervous serotonin: current experimental results. BE J. Psych. 155\(Suppl. 8), 41–51 (1989).
   Google Scholar
• Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T A Clinical trial of the efficacy and acceptability of d-fenfluramine in the treatment of neuroleptic induced obesity. Br. Psych. 153,208–213 (1988).
   PubMed Web of Science ®Google Scholar
• Wirth A. Long-term weight loss with sibutramine: A randomized controlled trial. JA/V/A 286,1331–1339 (2001) .
   Google Scholar
• Angelescu I, KLawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. I Clin. Bychopharm. 20,716–717 (2000).
   Google Scholar
• Cottingham EM. Metformin leads to weight loss in adolescents who gained weight on psychiatric drugs. American Psychiatric Association, Chicago, IL, USA (2000).
   Google Scholar
• Kusumakar V, Yatham LN, 0' Donovan C, Kutcher SR Topiramate augmentation: a preliminary open study of its effectiveness in women with refractory rapid cycling bipolar disorder and significant weight gain from previous treatment. Poster presented at the Third International Conference in Bipolar Disorder, Pittsburgh, PA, USA, June 17–19 (1999).
   Google Scholar
• Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can. PT& 45(2), 198 (2000).
   Google Scholar
• Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendorine side effects of neuroleptics. Clin. PTchophatm. 7,91–95 (1987).
   PubMed Web of Science ®Google Scholar
• Deberdt W Floris M, Lejeunne J. Effect of amantadine on weight gain during olanzapine treatment. Poster presentation at the US Psychiatric and Mental Health Congress, Nov 16–19 (2000).
   Google Scholar
• Wilcox JA, Tsuang J. Psychological effects of amantadine on psychotic subjects. Neuropsychobiology23, 144–146 (1990).
   PubMed Web of Science ®Google Scholar
• Brier A, Tanaka Y, Roychowdahury Clark S. Nazitidine for the Prevention of Olanzapine associated weight gain in schizophrenia and related disorders: A Randomized Controlled Double-blind Study. Presented at College of Psychiatric and Neurologic Pharmacisits, San Antonio, TX, USA, March 26–28 (2001).
   Google Scholar
• Stoa-Birketvedt G, Waldum HL, Vonen B, Florholmen J. Effect of cimetidine on basal and postprandial plasma concentrations of cholecystokinin and gastrin in humans. Acta Physiol. Scand. 159(4), 321–325 (1997).
   Google Scholar
• Stoa-Birketvedt G, Paus PN, Gnass R. Cimetidine reduces weight gain and improves metabolic control in overweight patients with Type 2 diabetes. j Obes. Relat. Metab. Disord. 22,1041-1045 (1998). no Cowan GSM Jr, Frank A. Medical management of obesity. CME Medscape (2001).
   Google Scholar